Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7503929 | 1.00 | ALDH1A1 (0.44) | ALDH1A1PKMHPGDGPR84MAPT | |
| SCHEMBL4521504 | 1.00 | ALDH1A1 (0.44) | ALDH1A1PKMHPGDGPR84MAPT | |
| SCHEMBL10088355 | 1.00 | ALDH1A1 (0.44) | ALDH1A1PKMHPGDGPR84MAPT | |
| SCHEMBL1148287 | 1.00 | ALDH1A1 (0.44) | ALDH1A1PKMHPGDGPR84MAPT | |
| SCHEMBL11933712 | 1.00 | ALDH1A1 (0.44) | ALDH1A1PKMHPGDGPR84MAPT | |
| SCHEMBL20915220 | 1.00 | ALDH1A1 (0.44) | ALDH1A1PKMHPGDGPR84MAPT | |
| SCHEMBL2703075 | 1.00 | ALDH1A1 (0.44) | ALDH1A1PKMHPGDGPR84MAPT | |
| SCHEMBL13519918 | 1.00 | ALDH1A1 (0.44) | ALDH1A1PKMHPGDGPR84MAPT | |
| SCHEMBL16837384 | 1.00 | ALDH1A1 (0.44) | ALDH1A1PKMHPGDGPR84MAPT | |
| SCHEMBL6227336 | 1.00 | ALDH1A1 (0.44) | ALDH1A1PKMHPGDGPR84MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048037-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | EPITRACKER INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12440473-B2 | Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain | Epitracker, Inc. (US) | 2025-10-14 | — | — | US | disclosed |
| US-11951088-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | Epitracker, Inc. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20210386710-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | Epitracker, Inc. | 2021-12-16 | — | — | US | disclosed |
| US-20210386710-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | Epitracker, Inc. | 2021-12-16 | — | — | US | disclosed |
| US-20200345676-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | Epitracker, Inc. | 2020-11-05 | — | — | US | disclosed |
| US-10792266-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | Epitracker, Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10792266-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | Epitracker, Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190117607-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | Epitracker, Inc. | 2019-04-25 | — | — | US | disclosed |
| US-20190117607-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | Epitracker, Inc. | 2019-04-25 | — | — | US | disclosed |
| US-20170239362-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2017-08-24 | — | — | US | disclosed |
| US-9695226-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2017-07-04 | — | — | US | disclosed |
| US-20160058879-A1 | Growth Hormone Compound Formulation | NOVO NORDISK HEALTHCARE AG (CH) | 2016-03-03 | — | — | US | disclosed |
| US-20140329750-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2014-11-06 | — | — | US | disclosed |
| US-8865868-B2 | Conjugated proteins with prolonged in vivo efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-8841249-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK A/S (DK) | 2014-09-23 | — | — | US | disclosed |
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2014-04-17 | — | — | US | disclosed |
| US-20120309944-A1 | Growth Hormones With Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2012-12-06 | — | — | US | disclosed |
| US-20120172303-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2012-07-05 | — | — | US | disclosed |
| US-20110223151-A1 | CONJUGATED PROTEINS WITH PROLONGED IN VIVO EFFICACY | NOVO NORDISK HEALTH CARE AG (CH) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329750-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | GHRHR, GHITM, SHBG | ALDH1A1 3861/4885PKM 3908/4885HPGD 1707/4885 |
| US-20120172303-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | GHRHR, GHITM, SHBG | ALDH1A1 3861/4885PKM 3908/4885HPGD 1707/4885 |
| US-20190117607-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | FABP1, FASN, GPR119 | ALDH1A1 1504/4885PKM 699/4885HPGD 1415/4885 |
| US-20120309944-A1 | Growth Hormones With Prolonged In-Vivo Efficacy | GHRHR, SHBG, GHSR | ALDH1A1 4411/4885PKM 4553/4885HPGD 1286/4885 |
| US-20210386710-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | SCD, FABP7, ELOVL1 | ALDH1A1 1447/4885PKM 1547/4885HPGD 1443/4885 |
| US-10792266-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | FABP1, FASN, GPR119 | ALDH1A1 1504/4885PKM 699/4885HPGD 1415/4885 |
| US-20170239362-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | ALDH1A1 3572/4885PKM 4391/4885HPGD 1096/4885 |
| US-11951088-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | FABP1, FASN, GPR119 | ALDH1A1 1504/4885PKM 699/4885HPGD 1415/4885 |
| US-20260048037-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | CNR1, CNR2, FFAR1 | ALDH1A1 1410/4885PKM 2072/4885HPGD 2073/4885 |
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | ALDH1A1 3572/4885PKM 4391/4885HPGD 1096/4885 |
| US-20160058879-A1 | Growth Hormone Compound Formulation | GHRHR, GHSR, GHITM | ALDH1A1 4350/4885PKM 2085/4885HPGD 277/4885 |
| US-20200345676-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | FABP1, FASN, GPR119 | ALDH1A1 1504/4885PKM 699/4885HPGD 1415/4885 |
| US-20110223151-A1 | CONJUGATED PROTEINS WITH PROLONGED IN VIVO EFFICACY | F13B, F13A1, F2 | ALDH1A1 2916/4885PKM 3946/4885HPGD 1468/4885 |
| US-12440473-B2 | Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain | SCD, FABP7, ELOVL1 | ALDH1A1 1447/4885PKM 1547/4885HPGD 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.